Joshua Fox to be Featured at NYBA 21st Annual Meeting in NYC

Joshua Fox to be Featured at NYBA 21st Annual Meeting in NYC

Firm News

WilmerHale is pleased to share that Partner Joshua Fox has been selected as a speaker at the New York Biotechnology Association (NYBA) 21st Annual Meeting, May 2-3, 2012 at the Marriott Marquis Hotel in New York City.

Fox will participate on a panel entitled, "Preparing for an IPO: Is Now the Right Time to Consider?" on May 2, from 3:30-4:45 p.m. The panel will explore the requirements to ready your company for an IPO, including board, legal, financial and accounting considerations, and walk you through the IPO process. It will also discuss market conditions and considerations as to when a company should contemplate a public offering.

Fox is a partner in WilmerHale's Emerging Company and Corporate Practices. He provides advice to public and private companies with respect to venture capital financings, mergers and acquisitions, public offerings, securities law compliance and general corporate matters. As a member of the Emerging Company Practice, Fox represents early-stage technology companies and provides advice to these companies in the areas of incorporation and startup, venture capital transactions, and mergers and acquisitions.

Dr. Francis Collins, director of the National Institutes of Health (NIH) will headline the meeting in a keynote address on Thursday, May 3. Keynote speakers for May include Dr. Prabhu Pingali, deputy director of the Gates Foundation and Dr. Marc Tessier-Lavigne, president of Rockefeller University. The NYBA 21st Annual Meeting is the largest bioscience conference in the Northeast, drawing hundreds of executive-level attendees from across the bioscience industry spectrum, including biotech, pharma, device and diagnostics, business development, research and academia.

Click here for more information.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.